However, in the context of pain–depression comorbidity, the function of monoaminergic neurotransmitter systems may be impaired (e.g., decreased 5-HT levels or reduced receptor sensitivity), thereby weakening the regulatory effects of oxytocin. This evidence concerns the gene OXT and depressive disorder.